BIOLOGICAL PROPERTIES OF SV40 EARLY PROTEINS
SV40 早期蛋白的生物学特性
基本信息
- 批准号:3165846
- 负责人:
- 金额:$ 21.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1978
- 资助国家:美国
- 起止时间:1978-01-01 至 1994-06-30
- 项目状态:已结题
- 来源:
- 关键词:antibody formation antigen receptors athymic mouse disease /disorder model gene expression genetic transcription hamsters immunochemistry laboratory mouse laboratory rabbit laboratory rat membrane activity molecular oncology mutant oncogenes oncogenic virus radiotracer simian virus 40 surface antigens tissue /cell culture transforming growth factors transforming virus tumor antigens viral leukemogenesis virus antigen virus genetics virus protein virus replication
项目摘要
The long-range goal of this project is to understand the transforming
interactions between DNA tumor virus and target cells. The approach has
been to define molecular interactions and biological functions expressed
by the SV40 transforming protein, large tumor antigen (T-ag). There is
evidence for multiple effects exerted by distinct T-ag subpopulations on
transformed cells, including possible role for plasma-membrane-associated
T-ag (pmT-ag). This renewal application focuses on questions fundamental
to understanding the molecular mechanisms of SV40 carcinogenesis. This
program will correlate T-ag structure and function with transformation
events.
The following specific aims are present. (1) The structure and function
of SV40 T-ag containing, membrane-associated protein complexes will be
analyzed. We have developed a butane extraction method that selectively
recovers membrane protein complexes that contain pmT-ag and p53-related
protein (p56). Other cellular components in the complexes (60K, 50K,
45K, 35K) will be identified; it is hypothesized they are members of a
receptor complex. the composition modifications, and biochemical
activities of pmT-ag-containing complexes will be investigated .
Possible involvement of T-ag in a growth-factor-like pathway will be
examined. (2) Transformation phenotypes of new in-phase deletion mutants
will be related to specific interactions of mutant T-89 with cellular
proteins and the plasma membrane. Different assays will distinguish T-ag
domain required for cell immortalization and phenotypic transformation.
Complementation transformation tests may permit assignment of T-ag
functions to categories defined by known oncogenes. Mutant T-ag
polypeptides will be characterized structurally and biochemically,
including complex formation with membrane proteins, and those analyses
correlated with transformation by the mutants. (3)Trafficking of SV40 T-
ag to the cell surface will be studied. Deletion mutants will reveal
possible effects of the short hydrophobic sequence in T-ag on transport
and membrane interaction. The potential involvement of cellular heat-
shock protein p73 (that bind T-ag) in pmT-ag transport will be addressed.
A role for O-glycosylation o T-ag in trafficking or membrane association
will be considered. (4) Cellular and molecular events involved in muoti-
stage carcinogenesis in livers of SV40 transgenic mice will be defined.
We have found that mice with the WT T-ag gene controlled by the alpha-1-
antitrypsin promoter develop liver tumors. New transgenic mice carrying
the p53 or mutants T-ag genes will be made. Various transgenic lines
will be crossed and pathology in progeny animal determined. The
expression of viral (pmT-ag and cellular (oncogenes) events will be
correlated with different stages of neoplastic progression. Hyperplastic
liver cells will be cultured to determine in vitro growth properties that
correspond to preneoplasia in vivo.
这个项目的长期目标是了解这种转变
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JANET S BUTEL其他文献
JANET S BUTEL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JANET S BUTEL', 18)}}的其他基金
相似海外基金
Development of back bone vectors for chimeric antigen receptors against key molecules, CD47 and CD24, activating macrophages
开发针对关键分子 CD47 和 CD24 的嵌合抗原受体的骨干载体,激活巨噬细胞
- 批准号:
23K06728 - 财政年份:2023
- 资助金额:
$ 21.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
CAREER: Engineering next-generation chimeric antigen receptors for cancer immunotherapy using phospho-proteomics
职业:利用磷酸蛋白质组学设计用于癌症免疫治疗的下一代嵌合抗原受体
- 批准号:
2145853 - 财政年份:2022
- 资助金额:
$ 21.83万 - 项目类别:
Continuing Grant
Construction of a drug discovery platform utilizing antigen receptors that regulate the quality of cancer immunity
利用调节癌症免疫质量的抗原受体构建药物发现平台
- 批准号:
22K06603 - 财政年份:2022
- 资助金额:
$ 21.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Engineering synthetic adhesion receptors to enhance the sensitivity of therapeutic chimeric antigen receptors
工程合成粘附受体以增强治疗性嵌合抗原受体的敏感性
- 批准号:
MR/W031353/1 - 财政年份:2022
- 资助金额:
$ 21.83万 - 项目类别:
Research Grant
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
- 批准号:
10701754 - 财政年份:2022
- 资助金额:
$ 21.83万 - 项目类别:
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
- 批准号:
10557760 - 财政年份:2022
- 资助金额:
$ 21.83万 - 项目类别:
Chimeric antigen receptors on regulatory T cells as a treatment strategy in auto-immune diseases.
调节性 T 细胞上的嵌合抗原受体作为自身免疫性疾病的治疗策略。
- 批准号:
437200 - 财政年份:2020
- 资助金额:
$ 21.83万 - 项目类别:
Studentship Programs
Molecualr imaging for development of chimeric antigen receptors (CARs) resistant to T cell exhaustion
用于开发抗 T 细胞耗竭的嵌合抗原受体 (CAR) 的分子成像
- 批准号:
20H03536 - 财政年份:2020
- 资助金额:
$ 21.83万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
- 批准号:
10542442 - 财政年份:2020
- 资助金额:
$ 21.83万 - 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
- 批准号:
10321545 - 财政年份:2020
- 资助金额:
$ 21.83万 - 项目类别: